Clinical Trials Browser

Phase 2 × INDUSTRY × Tumor-Agnostic × Clear all

NCT05968326 2026-04-13

IMCODE003

Phase 2 Recruiting

Adenocarcinoma

NCT06979596 2026-04-13

OMAHA-015

Phase 2 Recruiting

Neoplasms

NCT07209111 2026-04-13

KANDLELIT-014

Phase 2 Recruiting

Neoplasms

NCT05993299 2026-04-08

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Phase 2 Active not recruiting

7 enrolled 15 charts

Neoplasms

NCT06703346 2026-04-08

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Phase 2 Active not recruiting

Neoplasms

NCT06593522 2026-04-07

A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

Phase 2 Recruiting

Neoplasms

NCT03899155 2026-04-01

Pan Tumor Rollover Study

Phase 2 Recruiting

Neoplasms

NCT05999994 2026-03-27

CAMPFIRE

Phase 2 Recruiting

Neoplasms

NCT04639219 2026-03-23

DPT01

Phase 2 Active not recruiting

102 enrolled 18 charts

Neoplasm Metastasis

NCT06005974 2026-02-23

A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation

Phase 2 Terminated

Neoplasm Metastasis

NCT03964727 2026-01-30

TROPiCS-03

Phase 2 Active not recruiting

223 enrolled 31 charts

Neoplasm Metastasis

NCT03697304 2026-01-27

Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours

Phase 2 Completed

211 enrolled 23 charts

Neoplasm Metastasis

NCT05283226 2026-01-23

Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy

Phase 2 Recruiting

Carcinoma

NCT00781612 2025-12-24

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

Phase 2 Active not recruiting

Neoplasm Metastasis

NCT06107413 2025-12-12

Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

Phase 2 Active not recruiting

Neoplasms

NCT04452955 2025-12-02

A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors

Phase 2 Active not recruiting

Neoplasms

NCT04214288 2025-11-20

SERENA-2

Phase 2 Active not recruiting

240 enrolled 16 charts

Neoplasm Metastasis

NCT03498521 2025-11-19

CUPISCO

Phase 2 Completed

529 enrolled 16 charts

Neoplasms, Unknown Primary

NCT04819373 2025-11-12

BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors

Phase 2 Completed

Neoplasms

NCT06246110 2025-11-12

A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

Phase 2 Recruiting

Neoplasm Metastasis

NCT06175221 2025-09-15

Autologous TLPO Vaccine Basket

Phase 2 Terminated

Neoplasm Metastasis, Neoplasms

NCT05374915 2025-08-28

Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)

Phase 2 Active not recruiting

Neoplasm Metastasis

NCT06010342 2025-07-22

A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients

Phase 2 Recruiting

Neoplasms

NCT06926673 2025-07-03

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3

Phase 2 Completed

62 enrolled 36 charts

Neoplasms

NCT06790303 2025-06-04

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2

Phase 2 Terminated

8 enrolled 11 charts

Neoplasms

NCT06942767 2025-04-27

Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Phase 2 Not yet recruiting

Adenocarcinoma

NCT05673811 2025-04-16

VIRAGE

Phase 2 Completed

Neoplasm Metastasis, Neoplasms

NCT04976634 2025-04-06

MK-6482-016

Phase 2 Active not recruiting

Neoplasms

NCT04014075 2025-04-03

DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

Phase 2 Completed

79 enrolled 19 charts

Neoplasm Metastasis

NCT05126433 2025-02-28

JAZZ EMERGE201

Phase 2 Terminated

47 enrolled 16 charts

Neoplasm Metastasis

NCT00748709 2025-02-11

Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.

Phase 2 Terminated

20 enrolled 11 charts

Neoplasms

NCT04812535 2025-02-11

Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.

Phase 2 Terminated

30 enrolled 41 charts

Neoplasm Metastasis

NCT04050436 2025-01-27

CERPASS

Phase 2 Active not recruiting

Carcinoma, Carcinoma, Squamous Cell

NCT05097599 2025-01-08

StrataPATH

Phase 2 Terminated

Neoplasms

NCT01650194 2024-12-10

A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients

Phase 2 Completed

60 enrolled 24 charts

Neoplasms

NCT03760081 2024-11-13

A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors

Phase 2 Completed

19 enrolled 19 charts

Neoplasms

NCT04713371 2024-05-09

A Phase 2 Trial for Patients With Metastatic Solid Cancer

Phase 2 Active not recruiting

Neoplasm Metastasis

NCT04894994 2023-12-05

FLX475 in Combination With Ipilimumab in Advanced Melanoma

Phase 2 Terminated

6 enrolled 10 charts

Neoplasms

NCT03308942 2023-10-16

Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants

Phase 2 Completed

53 enrolled 35 charts

Neoplasms

NCT01192971 2023-03-03

HCC

Phase 2 Completed

Neoplasms

NCT02213133 2023-01-26

STARRS

Phase 2 Terminated

45 enrolled 12 charts

Carcinoma, Carcinoma, Squamous Cell

NCT05553808 2023-01-19

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1

Phase 2 Completed

105 enrolled 31 charts

Neoplasms

NCT02915783 2023-01-17

A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease

Phase 2 Completed

41 enrolled 11 charts

Neoplasm Metastasis

NCT03697707 2022-10-10

ADVANCE-II

Phase 2 Unknown

Neoplasm, Residual

NCT04985825 2022-09-13

I-PACE

Phase 2 Withdrawn

Carcinoma, Neoplasms

NCT02921919 2022-08-24

Open-Label Extension and Safety Study of Talazoparib

Phase 2 Completed

120 enrolled 16 charts

Neoplasms

NCT04003623 2022-05-10

Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)

Phase 2 Terminated

1 enrolled 2 charts

Neoplasm Metastasis

NCT02832167 2022-05-09

CheckMate 627

Phase 2 Completed

239 enrolled 22 charts

Neoplasms

NCT02366884 2022-04-06

Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011)

Phase 2 Unknown

Neoplasms

NCT04809012 2022-03-25

Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors

Phase 2 Withdrawn

Neoplasms